Upadhyay Suketu 4

What Happened
Suketu Upadhyay, a director of Vertex Pharmaceuticals (VRTX), was granted 80.508 deferred stock units (DSUs) on 2026-04-15. The grant is recorded at $442.50 per share for a total value of $35,625. This was an award/compensation (transaction code A) rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-04-15; filing date: 2026-04-17 (appears timely).
• Instrument: 80.508 deferred stock units (derivative award) at $442.50 per unit; total value $35,625.
• Shares owned after transaction: not reported in this Form 4.
• Footnote: Each DSU represents one share of common stock and will be paid out in common stock upon the earliest of (i) Mr. Upadhyay’s board service termination, (ii) a change of control, or (iii) his disability or death.
• Transaction type: Award/Grant (A); derivative, restricted until payout conditions are met.

Context
This is a typical director compensation grant (deferred stock units) and not an immediate purchase or sale. Because the DSUs convert to actual shares only upon specified events, they are restricted and do not indicate an immediate change in market exposure.